Cosmetic product claims implying drug-like benefits will continue to be on FDA’s enforcement radar, according to Office of Cosmetics and Colors Director Linda Katz.
Speaking March 3 at the American Conference Institute’s Legal, Regulatory and Compliance Forum on Cosmetics in New York, Katz discussed the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?